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Summary A urinary gonadotrophin peptide (UGP) was isolated and purified from semi-purified human
chorionic gonadotrophin (hCG), prepared from pregnancy urine. The peptide showed hCG-B subunit activity
and no hCG-alpha subunit activity as demonstrated by binding studies with the relevant antibodies. It had a
molecular weight significantly less than hCG-B subunit. The peptide was linked to thyroglobulin and this
conjugate used to immunise rabbits and mice. A radioimmunoassay (RIA) using 1251-UGP and the rabbit
antiserum (AK12) was used to monitor chromatographed urine fractions from patients with ovarian
carcinoma, seminoma and hydatidiform mole. UGP was also found in the urine extract of a healthy male, but
at a much lower level. In each case the UGP detected had the same molecular weight as the pregnancy
preparation and appeared to be the main gonadotrophin constituent in those urine samples. Initial
immunohistochemical screening of normal and neoplastic tissues with the rabbit antibody (AK12) showed
reactivity with some tumours including carcinomas of the lung, ovary, cervix and breast as well as
trophoblastic and germ cell tumours. Reactions with non-neoplastic tissues were confined to some specialised
epithelia and macrophage populations. A more comprehensive immunohistochemical study was made using a
monoclonal antibody to UGP (2C2), with a monoclonal antibody to conformational hCG (INN 13) and
another monoclonal antibody to free B subunit (1 E5) as controls. Similar patterns of reactivity were
produced by the AK12 and 2C2 antibodies in both neoplastic and non-neoplastic tissues. Additional tissues
were investigated with the three monoclonal antibodies. The 2C2 antibody reacted with 93% (77/83) of
tumours examined; the INN 13 antibody reacted with only the syncytiotrophoblast cells of choriocarcinoma,
hydatidiform mole, placental site trophoblastic tumour, and in one case of seminoma; the 1E5 reactivity was
confined to only choriocarcinoma syncytiotrophoblast cells.
Human chorionic gonadotrophin (hCG) is a glycoprotein
hormone consisting of 2 dissimilar subunits, alpha and beta,
which are joined non-covalently (Swaminathan & Bahl, 1970;
Morgan & Canfield, 1971; Pierce et al., 1971). In recent
years there have also been several reports of the presence in
urine, from normal pregnancy or hCG secreting neoplasms,
of an additional fragment with beta-subunit activity but
with a much lower molecular weight (Cole et al., 1988;
Papapetrou & Nicopoulou, 1986; Wehmann & Nisula, 1980;
Masure et al., 1981; Schroeder & Halter, 1983; Good et al.,
1977; Franchimont et al., 1972). In this paper the fragment is
referred to as Urinary Gonadotrophin Peptide (UGP).
This paper reports the production of UGP and specific
antibodies to it, which enabled the monitoring of chromato-
graphed urine samples from patients with different tumour
types; also the peptides detected were compared for homo-
geneity in terms of their molecular weight.
In view of the fact that several patients with different
neoplasms appeared to be producing UGP, it was decided to
do a more comprehensive study of this peptide using
immunohistochemistry in order to assess its potential as a
tumour marker.
Materials and methods
Sephadex G-100 column chromatography
The original source material for the isolation of UGP was a
commercial preparation of hCG (Pregnyl, 5,000U/ampoule
by bioassay from Organon, Oss, Netherlands). This is de-
rived from pooled collections of urines from pregnant
women and is partially purified. Ten ampoules were used
and these were dissolved in 0.05M phosphate buffer pH7.5
(2ml). The solution was chromatographed on a column
(85cm x 2.5cm) of Sephadex G-100 (Pharmacia, Uppsala,
Sweden). Each fraction was assayed using an antibody to the
beta-subunit (W14) and an antibody to the alpha-subunit
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(50/3). The different peaks were concentrated using ultra
filtration (YM-5 membrane, Amicon, Stonehouse, Gloucs,
UK).
Sodium dodecyl sulphate - Polyacrylamide slab gel
electrophoresis (SDS- PAGE)
Both samples and appropriate molecular weight markers
were reduced with mercaptoethanol and then separated by
10% PAGE (20% SDS). Protein bands were visualized with
Coomassie Blue. Proteins from an identical gel were trans-
ferred to nitrocellulose paper using the 'Western Blot' tech-
nique (Burnette, 1981). The proteins were overlaid with
either (i) a polyclonal rabbit antiserum (50/3) directed tow-
ards the alpha-subunit of hCG or (ii) a mouse monoclonal
antiserum (W14) directed towards the beta-subunit of hCG;
or (iii) a rabbit polyclonal antiserum (MW36) directed
towards intact hCG (this had antibodies to both the alpha-
and beta-subunits). The papers were then incubated with
either 1251 Protein A or 1251 rabbit anti-mouse, followed by
autoradiography. Additional gels were overlaid with 1251
Concanavalin A and autoradiographed to show the glyco-
protein bands containing either mannose or glucose residues.
Immunopurification against immobilized antibodies to hCG
beta subunit
Mouse monoclonal antibodies directed towards hCG -beta-
subunit (W14) were covalently linked to cyanogen bromide
activated Sepharose CL/4B (Pharmacia). Samples were
reacted with the immobilized antibodies and the bound
antigen eluted with 3M ammonium thiocyanate and desalted
immediately by use of a short column of Sephadex G-25
(Pharmacia).
Production of antibodies to UGP
Antisera were raised in both rabbits and mice. Immuno-
purified UGP was covalently linked to thyroglobulin (1:1 by
weight) using N-3-dimethyl aminopropyl carbodiimide
hydrochloride as the linking agent (Davis & Preston, 1981).
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The immunisation schedule for the rabbit (New Zealand
White) was as follows: (a) A primer injection (s.c.) of 40,ug
UGP-conjugate in Freund's complete adjuvant (Sigma,
Poole, Dorset, UK). (b) Four weeks later a booster injection
(s.c.) was administered, also comprising 40,ug in Freund's
incomplete adjuvant. Blood was drawn 2 weeks later and
then at fortnightly intervals to test for the production of
antibodies.
The immunisation schedule for the mice, for monoclonal
antibody production was as follows: (a) BALB/c mice
received an initial injection (s.c.) of 20pg UGP-thyroglobulin
conjugate in Freund's complete adjuvant. (b) Three weeks
later a booster injection (s.c.) of 10jig UGP-conjugate in
Freund's incomplete adjuvant was administered. (c) Three
weeks after the first booster injection, a second such injec-
tion (i.p.) was delivered, of 25jg UGP-conjugate in Freund's
incomplete adjuvant. Three days after the final boost the
mice were sacrificed and the spleen cells fused with the NS-1
myeloma cell line.
Radioimmunoassay for UGP
UGP (5jig) was radiolabelled with 1mCi 1251 (Amersham
International plc, Amersham, UK), using 'lodogen' (1,3,4,6-
tetrachloro-3a,6a-diphenylglycoluril) (Pierce Chemical Co.,
Cambridge, UK), immobilised on borosilicate glass tubes
(Fraker & Speck, 1978), an incorporation of 95% of the
radionuclide was obtained with a specific activity of
180,uCi jig-l. Rabbit antibody to UGP (AK12) was used at
a dilution giving 30% of maximum binding to the radio-
labelled antigen. Fractions were incubated overnight at room
temperature and then precipitated with goat anti-rabbit
immunoglobulin for 2h (at room temperature). Separation
of free and bound tracer was achieved by filtration through
glass fibre filters (GF/F, Whatman, Maidstone, Kent, UK).
Extraction of UGP from the urine of patients with different
neoplasms
Urine samples from patients each with a different neoplasm,
(i) ovarian carcinoma, (ii) seminoma and (iii) hydatidiform
mole, were used. In each case the UGP in the urine was
extracted using 2 vol of acetone to 1 vol of urine. The
precipitate was centrifuged and resuspended in a minimum
volume of 0.05M phosphate buffer, pH7.5. The procedure
then followed the same path as the UGP from the 'Pregnyl'
material (see above) except that the UGP was monitored by
the UGP-RIA. A urine extract from a healthy male was also
chromatographed.
Immunohistochemical characterisation
Formalin fixed, paraffin embedded sections were first
blocked with normal goat serum, incubated (30min) with
antibodies to UGP (Immuno purified-AK12) and then
further incubated (30min) with biotinylated goat anti-rabbit
IgG- containing normal human serum (Vector Laboratories,
Peterbrough, UK). Avidin-biotin peroxidase reagent (Vector
Laboratories) was applied (50min) and visualisation was
achieved using freshly prepared diamino- benzidine tetra-
hydrochloride (Sigma) (0.5mgml-1, containing 0.03%
hydrogen peroxide). Sections were counterstained with Coles'
Haematoxylin. Sections incubated with antibodies to intact-
hCG (R 185) were used for comparison.
Cryostat sections were fixed in formalin (10%, 30min),
blocked with normal horse serum and incubated (45min)
with one of the following monoclonal antibodies: anti
UGP(2C2); anti conformational hCG (INN 13) - (Serotec,
Kidlington, Oxford, UK) or anti free beta-subunit (IE5),
donated by M.B. Khazaeli, University of Birmingham,
Alabama. The sections were then further incubated (30min)
with biotinylated horse anti-mouse IgG, containing normal
human serum (Vector Labs.). The procedure was then as
above.
Immunohistochemical distribution of the antibodies was
assessed independently by two observers.
Results
The 'Pregnyl' material yielded three peaks as indicated in
Figure 1. (a) The major peak with an apparent mol. wt of
70,000. This had both alpha- and beta-subunit activity and
corresponded to the complete hCG molecule. (b) A minor
peak with an apparent mol. wt of 30,000. This had only
alpha-subunit activity and is probably free alpha-subunit. (c)
Another minor peak which had only beta-subunit activity
with an apparent mol. wt of 15,000 (considerably less than
whole beta-subunit). This was the UGP material.
The UGP was originally concentrated by ultra-filtration
with a PM-10 membrane (Amicon). This membrane allows
molecules of mol. wt less than 10,000 to pass through, it was
found that UGP was in this category. Therefore a YM-5
membrane (mol. wt cut-off 5,000) was used so that the UGP
was retained by ultra-filtration.
After SDS-PAGE (reducing conditions) the UGP material
resolved into 3 bands when visualized by Coomassie Blue
staining. Antibody overlay results showed only one band of
activity. This band corresponded to a mol. wt of less than
10,000 and showed activity only with the antibodies to the
beta-subunit or intact hCG. There was no binding with the
antibodies to the alpha-subunit (Figure 2).
Affinity chromatography of the 'Pregnyl'-derived UGP
produced only a small peak of unbound protein, as this
starting material was already in a semi-purified form. How-
ever this was not the case with the material extracted from
the neoplastic patients urine which showed very large
amounts of protein in the unbound fraction, with no UGP
activity.
Figures 3, 4 and 5 show the chromatography profiles of
urine from patients with ovarian carcinoma, seminoma and
hydatidiform mole. In each case the predominant gonado-
trophin was the UGP. The Ve/Vo ratio for UGP was 2.1 in
all three cases, demonstrating homogeneity in molecular size.
This was the same ratio as the UGP from the pregnancy
material.
The urine extract, from the healthy male, showed the
presence of UGP when chromatographed (Figure 6) but at
very much lower levels.
Immunohistochemical distribution*
AK12 antiserum bound to 26 out of 35 neoplasms examined.
Hydatidiform mole and choriocarcinoma showed intense
labelling of syncytiotrophoblast with a gradation of reac-
tivity in the cytotrophoblast layers. Strong reactions were
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Figure 1 Sephadex G-100 fractionation of 'Pregnyl' human
chorionic gonadotrophin (semi-purified pregnancy urine).
*A more comprehensive table of immunohistochemical distribu-
tion is available from the authors on request.URINARY GONADOTROPHIN PEPTIDE 283
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Figure 4 Urine extract chromatographed on Sephadex G-100
from a patient with a seminoma.
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Figure 5 Urine extract chromatographed on Sephadex G-100
from a patient with a hydatidiform mole.
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Figure 3 Urine extract chromatographed on Sephadex G-100
from a patient with ovarian carcinoma.
observed in squamous carcinomas of the cervix, clear cell
carcinomas of the ovary, some carcinomas of the stomach
and bronchioalveolar carcinomas of the lung (Figure 7).
Weaker reactions were noted in invasive carcinoma of the
breast, squamous carcinoma of the lung, adenocarcinoma of
the cervix and a yolk-sac tumour. Colonic, oesophageal and
some ovarian carcinomas showed little or no reaction. The
site of reactivity was either cytoplasmic, lumenal surface
associated or a combination of both. Of note was the
intracellular lumenal reactivity in gastric, oesophageal and
breast adenocarcinomas.
Reactivity with non-neoplastic tissues was most evident in
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Figure 6 Urine extract chromatographed on Sephadex G-100
from a healthy male individual.
normal trophoblast of first trimester placentae where syn-
cytiotrophoblast was labelled strongly both on the mem-
brane and in the cytoplasm, with cytotrophoblast showing
weaker cytoplasmic positivity. Other reactions were confined
to mucous secreting epithelium of the stomach and duo-
denum, Nabothian follicle in the cervix and ductal epithe-
lium of the breast. Variable positivity was observed in gastric
parietal cells, spermatogonia and interstitial cells of the
testis. Consistent reactivity was seen in polymorphonuclear
neutrophils, sinus histiocytes in lymph node and in other
macrophages, notably in the lung.
2C2 monoclonal antibody reacted with 77 of 83 tumours
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Figure 7 Immunoperoxidase staining with AK12 antiserum of
(a) Moderately differentiated adenocarcinoma of the stomach
showing apical surface positivity (x 100). (b) A bronchioalveolar
carcinoma of the lung showing intense cytoplasmic and mem-
brane reactivity ( x 100).
examined. The villous trophoblast of hydatidiform moles
and choriocarcinomas showed similar reactions, with strong
binding to syncytiotrophoblast and weaker positivity of
cytotrophoblast. The intermediate trophoblast of placental-
site trophoblastic tumours was labelled intensely on the cell
membrane. Of the other tissues, significant reactions were
observed in all breast ductal carcinomas, adeno and squa-
mous carcinomas of the lung, adenocarcinomas of the colon,
stomach, pancreas, ovary and endometrium (Figure 8).
Germ cell tumours were variably positive. Mature epithelium
in differentiated teratomas was often strongly positive with
generalised reactions in yolk-sac tumours and embryonal
carcinomas. Seminomas were either negative or displayed
focal weak reactions, however, the stromal elements often
showed distinctive positivity.
The cellular location of binding of 2C2 was again variable.
In adenocarcinomas of the large bowel positivity was mainly
confined to the glandular lumenal surface. The pattern of
distribution in squamous carcinomas of the lung, yolk-sac
tumour and a granulosa cell tumour of the ovary, was
predominantly membranous. Adenocarcinomas of the breast
and lung and squamous carcinomas of the cervix also
showed strong labelling of both membrane and cytoplasm.
Serous cystadenocarcinoma of the ovary, adenocarcinoma of
the endometrium and a yolk-sac tumour showed perinuclear
localisation.
2C2 consistently labelled syncytiotrophoblast membrane
and cytoplasm in both first trimester and term placentae
with the cytotrophoblast of early placentae clearly labelled
on the membrane. In other non-neoplastic tissues examined
reactions were observed in stratified squamous epithelium of
oesophagus, vagina and skin, glandular epithelium of endo-
metrium, stomach, cervix, breast, colon, lung and weakly in
the exocrine portion of the pancreas. Respiratory epithelium
was labelled variably. Alveolar macrophages were strongly
labelled with the alveolar membranes always negative. Whilst
bile duct epithelium was clearly labelled the reaction of
hepatic parenchyma was either negative or equivocal. Equi-
vocal reactions were also noted in renal tubular epithelium,
but the glomerular endothelium always displayed a discrete
positivity. The endothelium lining vascular spaces in both
non-neoplastic and neoplastic tissues, including an intra-
muscular haemangioma, was often labelled although variable
in both intensity of reaction and extent. In reactive lymph
nodes 2C2 gave a distinctive fibrillary pattern of reaction
with a few cells within germinal centres. A similar fibrillary
reaction was evident in peripheral nerves and characteristic
of neural differentiation seen in mature cystic teratomas.
In comparison with the pattern of reactivity observed with
the AK-12 and 2C2 antibodies, all non-trophoblastic tissues
showed negative binding with both the antibodies to confor-
mational hCG (INN 13) and those to the free beta subunit
(1E5).
In first trimester placentae, hydatidiform mole and chorio-
carcinoma, the distribution of reactivity with INN 13 was
confined to the syncytiotrophoblast membrane with only
weak or equivocal reaction with underlying cytotrophoblast.
No reaction was seen with the cytotrophoblast of placental
site reaction and placental site trophoblastic tumour.
lE5 showed focal positivity in syncytiotrophoblast only.
Discussion
UGP appears to be a normal peptide since 80/80 healthy
individuals, when measured by the UGP- RIA, expressed
levels of UGP (results to be reported in later manuscript)
and it was possible to purify UGP from the urine of a
healthy male with a typical normal UGP level. However the
levels of UGP excreted in urine appears to increase in
patients with active neoplasms. Of the patients whose urines
were extracted, the patient with ovarian carcinoma had levels
ten times greater than the healthy individual; the seminoma
patient had levels one hundred times greater and the patient
with hydatidiform mole had one hundred and fifty times
greater urinary UGP than the healthy male.
The gel chromatography shows UGP to have an apparent
mol. wt of 15,000 but this may be an overestimate since the
apparent molecular weights of hCG and of its subunits by
this method are all considerably more than their actual
molecular weights. Electrophoresis of UGP under reduced
conditions, shows UGP separating into three distinct bands
with the active epitope residing with the smallest molecular
weight band.
Analysis of the immunohistochemical profile of both
AK12 and 2C2 antibodies conclusively showed that these
antibodies react differently to those directed against intact
hCG or its free beta-subunit. The binding of antibodies to
intact hCG and its free beta-subunit was limited to normal
and neoplastic trophoblast, whilst the binding associated
with the anti-UGP antibodies was much more widespread.
Expression of UGP observed immunohistochemically in
normal tissues is consistent with the findings that UGP was
present in the urine of healthy individuals (by RIA) and
appears to be a normal peptide. Reactions with neoplastic
tissues were stronger and more extensive than those seen in
their normal counterparts. Many of the neoplastic tissues
that showed strong reactivity with the UGP antibodies are
not tumours usually associated with the production of
gonadotrophins.
Immunohistochemical reactivity with tumour sections sug-
gests that UGP is already present within the cells of many
different neoplasms that showed negative reactivity with
both the antibodies to conformational hCG and to the free
beta-subunit. Therefore, the presence of UGP in urine isURINARY GONADOTROPHIN PEPTIDE 285
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Figure 8 Immunoperoxidase staining with 2C2 antibody of (a) Non-neoplastic breast tissue showing uniform reactivity with duct
and acinar epithelium (x 64). (b) Invasive adenocarcinoma of the breast showing strong reactivity with cell membranes and
cytoplasm ( x 100). (c) Poorly differentiated invasive adenocarcinoma of the breast showing strong labelling of intracytoplasmic
lumena (x 100). (d) Complete hydatidiform mole showing reactivity with syncytiotrophoblast and focally with cytotrophoblast
( x 100). (e) Poorly differentiated adenocarcinoma of the endometrium showing characteristic juxtanuclear reactivity ( x 250). (f)
Moderately differentiated adenocarcinoma of the colon showing localisation of tumour cell membranes. Note necrotic glandular
debris is negative ( x 64). (g) Poorly differentiated adenocarcinoma of the pancreas showing positivity of tumour cell membranes
(x 100). (h) Yolk-sac tumour showing uniform membrane reaction (x 100).
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unlikely to be duc to a breakdown of either hCG or beta-
subunit by the kidney as has been suggested (Papapetrou &
Nicopoulou, 1986; Wehman & Nisula, 1980). Studies of the
carbohydrate moieties (Nisula et al., 1988) of B-core peptide
(which exhibits many similarities with UGP) have shown
that the ConA binding oligosaccharides of hCG and hCG
beta-subunit, appear in urine, with intact sialic acid-
galactose-containing antennae, whilst B-core peptide in urine,
is virtually devoid of sialic acid and galactose. This would
suggest that if B-corc peptide was a breeakdown product of
hCG, a different excretory pathway must be used to cleave
the carbohydrate.
The elevated levels of UGP extracted from the urine of
patients with neoplasms, together with the widespread distri-
bution of UGP found in a variety of human cancers, as
demonstrated by immunohistochemistry, could make this a
potentially useful marker for tumour detection by immuno-
assay or radioimmunolocalisation.
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